CML Publications from Africa

• Introducing diagnostic testing for chronic myeloid leukemia in a public hospital setting in Western Kenya
  Orido M et al. Arch Pathol Lab Med, July 2025 – open access publication
• Budget impact analysis of treatment-free remission in chronic myeloid leukemia patients treated with nilotinib in Tunisia
  Hizem A et al. J Cancer Policy, July 2025 (epub ahead of print)
• Unveiling the burden of leukemia in Eritrea (2010-2020): Chronic leukemia stability, rising ALL incidence, and the enigma of CML in a low-resource setting
  Abraha DM et al. Cancer Rep (Hoboken), June 2025
• Current and future of targeted therapies against BCR::ABL kinases – Review
  Jayaval S et al. J Egypt Natl. Canc Inst, April 2025 – open access publication
• The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukemia patient cohort
  Kenmogne VL et al. Sci Rep, March 2025 – open access publication
  

• Assessment of treatment outcomes in chronic myeloid leukemia patients on tyrosine kinase inhibitors: Insights from a resource limited setting
  Awlachew WY et al. Cancer Med, February 2025 – open access publication
• Haemolytic anemia in a patient of chronic myeloid leukemia: an unrecognised side-effect
  Jamal I et al. Niger Med J, January 2025 – open access publication
  
• Early molecular response to imatinib first-line therapy and predictive factors of poor outcomes for chronic myeloid leukemia patients in Cote d’Ivoire
  Koffi KG et al. Adv Hematol, December 2024 – open access publication
• Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia
  Mongoura SA et al. Cancer Chemother Pharmacol, December 2024 – open access publication

• Health-related quality of life and financial burden in Ethiopian patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors:A cross sectional study
  Tadesse F et al. JCO Global Oncol, November 2024 – open access publication
  
• Correlation of T regulatory cells, cytotoxic T-lymphocyte-associated antigen 4, and transforming growth-factor-beta1 with treatment response in patients with CML receiving dasatinib therapy
  Singh A et al. Ann Afr Med, Oct 2024 (epub ahead of print) – open access publication
• Late presentation of chronic myeloid leukemia patients in a low-income country: The prognostic implications and impact on treatment outcome
  Nelson EA et al. BMC Res Notes, Sept 2024 – open access publication
• Novel ABL1 mutation in a Moroccan CML patient with imatinib resistance
  El Bouchikhi I et al. Cancer Genet, Sept 2024 (epub ahead of print) – open access publication
• Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa
  Ayalew ZS et al. EJHaem, July 2024, eCollection Aug 2024 – open access publication
• Prognostic role of human leukocyte antigen alleles and cytokine single-nucleotide polymorphisms in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor drugs
  Birru SK et al. Genes(Basel), June 2024 – open access publication
• Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation of a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study
  Urgessa F et al. BMC Cancer, April 2024 – open access publication
• Cytogenetic and epidemiological profile of chronic myeloid leukemia in Morocco
  Benchikh S et al. Ann Hematol, April 2024 (epub ahead of print)
• A study to explore the role of IDH1 (R132) mutation on imatinib toxicity and effect of ABCG2/OCT1 expression on N-Desmethyl imatinib plasma level in Egyptian chronic myeloid leukemia patients
  Sabri A et al. Drug Res (Stuttg.), March 2023
• Assessment of molecular response to tyrosine kinase inhibitors in Tunisian patients with chronic myeloid leukemia
  Frikha R et al. J Oncol Pharm Pract, December 2022
• A ten-year experience of treating chronic myeloid leukemia in rural Rwanda: Outcomes and insights for a changing landscape
  Morgan J et al. JCO Glob Oncol, July 2022
• Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study
  McLigeyo A et al. BMC Cancer, February 2022 – open access publication
• Spectrum of BCR-ABL mutations and treatment outcomes in Ethiopian Imatinib-resistant patients with chronic myeloid leukemia
  Tadesse F et al. JCO Glob Oncol, July 2021 - open access publication
• Managing pediatric chronic myeloid leukemia in Africa: the Botswana experience with two cases
  Kaang T et al. Pediatr Hematol Oncol, March 2021 (epub ahead of print)
• Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
  Nasser A et al. Blood Adv, March 2021 – open access publication
• Imatinib in the treatment of chronic myeloid leukemia in Morocco
  Dakkoune M et al. Bull Cancer, September 2020 (in French)
• Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukemia patients treated with imatinib and barriers to access treatment
  Henke O et al. ecancer, August 2020 – open access publication
• Micro RNA 30a mediated autophagy and imatinib response in Egyptian chronic myeloid leukemia patients
  Khalil NA et al. Indian J Hematol Blood Transfus, July 2020
• Two decades of experience in a combined adult/pediatric allogeneic hematopoietic stem cell transplantation center in Algiers, Algeria
  Benakli M et al. Ann Hematol, March 2020
• The prognostic significance of TET2 single nucleotide polymorphism in Egyptian chronic myeloid leukemia
  Hamed NA et al. Mediterr J Hematol Infect Dis, January 2020 – open access publication
• Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia in Abidjan, Ivory Coast
  Silué DA et al. Bull Cancer, June 2019 (in French)
• Acute ischemic intestinal necrosis as a rare side effect of nilotinib
  Li L et al. Niger J Clin Pract, January 2019
• Detection of BCR-ABL1 fusion gene transcripts in the saliva of Nigerian patients with chronic myeloid leukemia
  Uzoma IC et al. Niger J Clin Pract, January 2019
• Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
  Adehin A et al. Leuk Lymphoma, May 2018
  (epub ahead of print)
• Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience)
  Ben Lakhal R et al. Ann Hematol, January 2018
  (epub ahead of print)
• Population pharmacokinetics of imatinib in Nigerians with chronic myeloid leukemia: Clinical implications for dosing and resistance
  Adeagbo BA et al. J Clin Pharmacol, December 2017
• Preliminary data on mircoRNA profiles in a group of South African patients diagnosed with chronic myeloid leukemia
  Prinsloo A et al. Mol Clin Oncol, September 2017 
• Downregulation of miR-451 in Tunesian chronic myeloid leukemia patients: potential implications in imatinib resistance
  Soltani I et al. Hematology, May 2018 
• hOCT1 gene expression predict for optimal response to imatinib in Tunisian patients with chronic myeloid leukemia
  Ben Hassine I et al. Cancer Chemother Pharmacol, April 2017 
• Epidemiological approach of chronic myeloid leukemia: Algerian-Tunesian Study
  Djouadi K et al. Blood, December 2016 
• Evaluation of the imatinib treatment of patients followed up for chronic myelogenous leukemia in Algeria
  Djouadi K et al. Blood, December 2016 
• Influence of CYP3A*3 and ABCB1 C3435T on clinical outcomes and through plasma concentrations of imatinib in Nigerians with chronic myeloid leukemia
  Adeagbo BA et al. J Clin Pharm Ther, October 2016
• Simple HPLC-UV method for pharmacokinetic studies of imatinib in the presence of common antimalarial agents
  Adeagbo BA et al. Journal of Liquid Chromatography & Related Technologies 2015, 38:1194-1198

 {rscomments off}